Editorial
(J)ALEX the great: a new era in the world of ALK inhibitors
Abstract
Anaplastic lymphoma kinase (ALK) gene rearrangement defines a recently identified molecular subtype of non-small cell lung cancer (NSCLC), which accounts for 4–5% of all non-squamous NSCLC (1).
